This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Geisler, J. Articles by Lønning, P. E. Search for Related Content PubMed PubMed Citation Articles by Geisler, J. Articles by Lønning, P. E.

Influence of Neoadjuvant Anastrozole (Arimidex) on Intratumoral Estrogen Levels and Proliferation Markers in Patients with Locally Advanced Breast Cancer¹

Departments of Oncology [J. G., H. B., P. E. L.], and Surgery [B. L.], Haukeland University Hospital, N-5021 Bergen, Norway; Academic Department of Biochemistry, Royal Marsden Hospital, London, SW3 6JJ, United Kingdom [S. D., M. D.]; and Department of Oncology, The Norwegian Radiumhospital, N-0310 Oslo, Norway [L. O.]

Anastrozole (Arimidex) is a novel, selective, and potent aromatase inhibitor used for the treatment of postmenopausal breast cancer. The drug has been shown to inhibit in vivo aromatization by 96–97% and to suppress plasma estrogen levels by 84–94%. However, the effects of anastrozole on intratumoral estrogen levels have not been studied. Here we report the effects of neoadjuvant treatment with anastrozole on intratumoral levels of estrone (E₁), estradiol (E₂), and estrone sulfate (E₁S), measured by a highly sensitive RIA following a multistep purification procedure involving high-pressure liquid chromatography. Tumor tissue was obtained prior to treatment and after 15 weeks on therapy with anastrozole (1 mg once daily) from 12 postmenopausal women with locally advanced breast cancer (T₃-T₄ and/or N₂). Pretreatment tissue levels of E₂, E₁, and E₁S were 217.9 (69.8–679.9), 173.6 (83.9–358.9), and 80.7 (31.4–207.3) fmol/g tissue (geometric mean values with 95% confidence interval, respectively). Treatment with anastrozole suppressed tissue E₂, E₁, and E₁S levels by 89.0% (73.2–95.5%), 83.4% (63.2–92.5%), and 72.9% (47.3–86.1%), respectively, compared with baseline levels, with no significant difference between responders and nonresponders. Plasma levels of E₂, E₁, and E₁S were suppressed by 86.1, 83.9, and 94.2%, respectively. Anastrozole caused a decrease in the immunoexpression of the proliferation markers Ki67 and pS2 in all of the patients, with a trend for a more profound suppression in those achieving an objective response. The mean percentage of apoptotic cells was found to be decreased in responders and increased in nonresponders after 15 weeks of anastrozole therapy. Our results reveal anastrozole to cause a significant suppression of tissue estrogen levels and to influence the biology of primary estrogen receptor-positive breast cancers in postmenopausal women.

This article has been cited by other articles:

				J. Geisler, H. Helle, D. Ekse, N. K. Duong, D. B. Evans, Y. Nordbo, T. Aas, and P. E. Lonning Letrozole is Superior to Anastrozole in Suppressing Breast Cancer Tissue and Plasma Estrogen Levels Clin. Cancer Res., October 1, 2008; 14(19): 6330 - 6335. [Abstract] [Full Text] [PDF]

				W. R. Miller, J. Bartlett, A. M. H. Brodie, R. W. Brueggemeier, E. di Salle, P. E. Lonning, A. Llombart, N. Maass, T. Maudelonde, H. Sasano, et al. Aromatase Inhibitors: Are There Differences Between Steroidal and Nonsteroidal Aromatase Inhibitors and Do They Matter? Oncologist, August 1, 2008; 13(8): 829 - 837. [Abstract] [Full Text] [PDF]

				V. Cappelletti, M. Gariboldi, L. De Cecco, S. Toffanin, J. F Reid, L. Lusa, E. Bajetta, L. Celio, M. Greco, A. Fabbri, et al. Patterns and changes in gene expression following neo-adjuvant anti-estrogen treatment in estrogen receptor-positive breast cancer Endocr. Relat. Cancer, June 1, 2008; 15(2): 439 - 449. [Abstract] [Full Text] [PDF]

				A. Kendall and M. Dowsett Novel concepts for the chemoprevention of breast cancer through aromatase inhibition. Endocr. Relat. Cancer, September 1, 2006; 13(3): 827 - 837. [Abstract] [Full Text] [PDF]

				C K Hilleson-Gayne and J A Clapper Effects of decreased estradiol-17{beta} on the serum and anterior pituitary IGF-I system in pigs J. Endocrinol., December 1, 2005; 187(3): 369 - 378. [Abstract] [Full Text] [PDF]

				A. Urruticoechea, I. E. Smith, and M. Dowsett Proliferation Marker Ki-67 in Early Breast Cancer J. Clin. Oncol., October 1, 2005; 23(28): 7212 - 7220. [Abstract] [Full Text] [PDF]

				C J Fabian, B F Kimler, M S Mayo, and S A Khan Breast-tissue sampling for risk assessment and prevention Endocr. Relat. Cancer, June 1, 2005; 12(2): 185 - 213. [Abstract] [Full Text] [PDF]

				J. Geisler and P. E. Lonning Aromatase Inhibition: Translation into a Successful Therapeutic Approach Clin. Cancer Res., April 15, 2005; 11(8): 2809 - 2821. [Abstract] [Full Text] [PDF]

				V. N. Kristensen, T. Sorlie, J. Geisler, A. Langerod, N. Yoshimura, R. Karesen, N. Harada, P.E. Lonning, and A.-L. Borresen-Dale Gene Expression Profiling of Breast Cancer in Relation to Estrogen Receptor Status and Estrogen-Metabolizing Enzymes: Clinical Implications Clin. Cancer Res., January 15, 2005; 11(2): 878s - 883s. [Abstract] [Full Text] [PDF]

				V. Cappelletti, L. Celio, E. Bajetta, A. Allevi, R. Longarini, P. Miodini, R. Villa, A. Fabbri, L. Mariani, R. Giovanazzi, et al. Prospective evaluation of estrogen receptor-{beta} in predicting response to neoadjuvant antiestrogen therapy in elderly breast cancer patients Endocr. Relat. Cancer, December 1, 2004; 11(4): 761 - 770. [Abstract] [Full Text] [PDF]

				J. S. Tobias Recent advances in endocrine therapy for postmenopausal women with early breast cancer: implications for treatment and prevention Ann. Onc., December 1, 2004; 15(12): 1738 - 1747. [Abstract] [Full Text] [PDF]

				A. U. Buzdar Data from the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trial: Implications for Use of Aromatase Inhibitors in 2003 Clin. Cancer Res., January 1, 2004; 10(1): 355S - 361S. [Abstract] [Full Text] [PDF]

				M. J. Ellis, A. Coop, B. Singh, Y. Tao, A. Llombart-Cussac, F. Janicke, L. Mauriac, E. Quebe-Fehling, H. A. Chaudri-Ross, D. B. Evans, et al. Letrozole Inhibits Tumor Proliferation More Effectively than Tamoxifen Independent of HER1/2 Expression Status Cancer Res., October 1, 2003; 63(19): 6523 - 6531. [Abstract] [Full Text] [PDF]

				T. Tominaga, I. Adachi, Y. Sasaki, T. Tabei, T. Ikeda, Y. Takatsuka, M. Toi, T. Suwa, and Y. Ohashi Double-blind randomised trial comparing the non-steroidal aromatase inhibitors letrozole and fadrozole in postmenopausal women with advanced breast cancer Ann. Onc., January 1, 2003; 14(1): 62 - 70. [Abstract] [Full Text] [PDF]

				M. Dowsett Preoperative Models to Evaluate Endocrine Strategies for Breast Cancer Clin. Cancer Res., January 1, 2003; 9(1): 502S - 510S. [Abstract] [Full Text] [PDF]